Vutrisiran for transthyretin amyloid cardiomyopathy
Cardiovascular
1 July 2026
-
Published on 01 Jul 2026
Last Updated on 01 Jul 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Vutrisiran 25 mg/0.5 mL injection for transthyretin amyloid cardiomyopathy.
Funding status
Vutrisiran 25 mg/0.5 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.
Patient must be undergoing treatment with vutrisiran as a monotherapy (i.e. not in combination with any other disease modifying medicines for amyloidosis disorders), and treatment should be used in line with the additional clinical criteria listed in the Annex.
Guidance_Vutrisiran for transthyretin amyloid cardiomyopathy (Published 1 Jul 2026) [PDF, 217.94 KB]
